Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality Home
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #FDA Approval #Quarterly Results #Phase 3 Trials #Cancer

Tag: IT Security Incident

Business Technology

Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark

  • By BiotechReality Business Intelligence Desk
  • 12 June 2026
Novo Nordisk Information

Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected.

Tagged Cyber Attack, IT Security Incident, Novo Nordisk
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

Novartis Q3 2026 Results: Kisqali and Kesimpta Lift Sales as Novartis Raises Full-Year Core Operating Income Guidance
Business Healthcare & Pharmaceuticals News

Novartis Q3 2026 Results: Kisqali and Kesimpta Lift Sales as Novartis Raises Full-Year Core Operating Income Guidance

28 October 202628 October 2026
BiotechReality Business Intelligence Desk
IQVIA Q3 2026 Results: IQVIA Holdings Reports $4,428 Million Revenue and Raises Full-Year 2026 Guidance
Business CRO Healthcare & Pharmaceuticals News

IQVIA Q3 2026 Results: IQVIA Holdings Reports $4,428 Million Revenue and Raises Full-Year 2026 Guidance

27 October 202627 October 2026
BiotechReality Business Intelligence Desk
Pfizer TALZENNA XTANDI Approval: FDA Clears Combination for an Earlier Metastatic Prostate Cancer Setting
News Healthcare & Pharmaceuticals Oncology Regulatory Approval

Pfizer TALZENNA XTANDI Approval: FDA Clears Combination for an Earlier Metastatic Prostate Cancer Setting

26 October 202627 October 2026
Regulatory Intelligence Desk
Eli Lilly olomorasib ESMO 2026 Data Show Durable First-Line Activity in KRAS G12C-Mutant NSCLC
Clinical Data Healthcare & Pharmaceuticals News

Eli Lilly olomorasib ESMO 2026 Data Show Durable First-Line Activity in KRAS G12C-Mutant NSCLC

25 October 202625 October 2026
Clinical Trials & Data Desk
Johnson & Johnson ESMO 2026: JNJ-6143 RIPTAC Debut, RYBREVANT FASPRO and ERLEADA Lead Solid Tumor Slate
Clinical Data Business Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson ESMO 2026: JNJ-6143 RIPTAC Debut, RYBREVANT FASPRO and ERLEADA Lead Solid Tumor Slate

24 October 202624 October 2026
Clinical Trials & Data Desk
Eli Lilly Sofe-M Plus Bevacizumab Delivers 79% Response Rate in Platinum-Sensitive Ovarian Cancer at ESMO 2026
Clinical Data Clinical Trials Healthcare & Pharmaceuticals News Oncology

Eli Lilly Sofe-M Plus Bevacizumab Delivers 79% Response Rate in Platinum-Sensitive Ovarian Cancer at ESMO 2026

24 October 202624 October 2026
Clinical Trials & Data Desk
Advertisement
BiotechReality JobFinder

  • Senior Product Analyst – Novartis, India
    25 October 2026
  • Rare Disease Medical Science Liaison (MSL) – Amgen, Japan
    20 October 2026
  • Clinical Project Management Director – IQVIA
    16 October 2026
  • Senior Manager, Global Digital Marketing – Lonza
    11 October 2026
  • Commercial Product Manager – Centrifuge – ThermoFisher, Singapore & Malaysia
    7 October 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter